Structure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low - Time to Sell?

Key Points

• Structure Therapeutics shares fell 5.8% to a new 52-week low of $25.49, well below their 50-day and 200-day moving averages of $43.43 and $45.17, respectively.
• Despite the decline and a quarterly EPS loss of $0.49 that missed estimates, analysts maintain an overall “Moderate Buy” rating with an average price target of $110.91.
• The clinical-stage biotech is developing GSBR-1290, an oral GLP-1 drug candidate for obesity and type 2 diabetes; institutional investors and hedge funds own approximately 91.78% of the stock.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price hit a new 52-week low during trading on Thursday. The stock traded as low as $25.49 and last traded at $25.61, with a volume of 205518 shares trading hands. The stock had previously closed at $26.68.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research report on Friday, August 7th. Citizens Jmp reaffirmed a "market outperform" rating and issued a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th. HC Wainwright reaffirmed a "buy" rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings upgraded shares of Structure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday. Finally, Wall Street Zen downgraded shares of Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $110.91.

Structure Therapeutics Trading Down 5.8%

The stock has a market cap of $1.75 billion, a PE ratio of -25.20 and a beta of -1.30. The company has a fifty day moving average of $43.43 and a 200-day moving average of $45.17.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). As a group, research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC acquired a new position in shares of Structure Therapeutics in the first quarter worth $28,000. IFP Advisors Inc acquired a new stake in shares of Structure Therapeutics in the second quarter valued at $46,000. Assetmark Inc. boosted its holdings in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company's stock valued at $123,000 after purchasing an additional 449 shares during the period. Janney Montgomery Scott LLC purchased a new position in Structure Therapeutics in the first quarter valued at $329,000. Finally, Cetera Investment Advisers grew its stake in Structure Therapeutics by 17.0% during the 1st quarter. Cetera Investment Advisers now owns 7,720 shares of the company's stock worth $372,000 after purchasing an additional 1,124 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.